Handan Ozturk1, Bengusu Mirasoglu2,3, Samil Aktas2. 1. Ankara Numune Research and Training Hospital, Underwater and Hyperbaric Medicine Department, Ankara, Turkey. 2. Istanbul University, Istanbul Faculty of Medicine, Underwater and Hyperbaric Medicine Department, Istanbul, Turkey. 3. Corresponding author: Associate Professor Bengusu Mirasoglu, Istanbul Tip Fakultesi, Sualti Hekimligi ve Hiperbarik Tip Anabilim Dali, 34093 Fatih, Istanbul, Turkey, bengusu.mirasoglu@istanbul.edu.tr.
Abstract
INTRODUCTION: Intractable haemorrhagic cystitis (HC) is a serious complication of chemotherapy (CT) and haematopoietic stem cell transplantation (HSCT). Hyperbaric oxygen treatment (HBOT) is a promising treatment option based on the similarities in injury pattern and observed histological changes with radiation induced HC, which is an approved indication. We present our experience with HBOT in HC occurring after CT and HSCT. METHODS: Medical files of patients who underwent HBOT between the years 2000-2020 for HC that developed after chemotherapy and/or HSCT were reviewed. Demographic data, primary diagnosis, history of HC and details of HBOT were documented. Treatment outcomes were grouped as complete and partial healing, no response and deterioration. RESULTS: Twenty-five patients underwent a median of 12 HBOT sessions for HC occurring after CT and HSCT. Complete healing was observed in 11 patients whereas haematuria improved in seven patients. HC grades after HBOT were significantly better than referral grades. A significant correlation was shown with the number of HBOT sessions and change in haematuria. Patients who underwent seven or more HBOT sessions benefitted most. CONCLUSIONS: HBOT appears to be a safe and effective treatment for refractory HC following CT and HSCT. Higher quality evidence would be needed to prove efficacy. However, given the difficulty of conducting randomised controlled trials on such a vulnerable and small group of patients with few treatment options, and given the consistency of current observational evidence, HC occurring after CT and HSCT may be considered as an optional or investigational indication for HBOT. Copyright: This article is the copyright of the authors who grant Diving and Hyperbaric Medicine a non-exclusive licence to publish the article in electronic and other forms.
INTRODUCTION: Intractable haemorrhagic cystitis (HC) is a serious complication of chemotherapy (CT) and haematopoietic stem cell transplantation (HSCT). Hyperbaric oxygen treatment (HBOT) is a promising treatment option based on the similarities in injury pattern and observed histological changes with radiation induced HC, which is an approved indication. We present our experience with HBOT in HC occurring after CT and HSCT. METHODS: Medical files of patients who underwent HBOT between the years 2000-2020 for HC that developed after chemotherapy and/or HSCT were reviewed. Demographic data, primary diagnosis, history of HC and details of HBOT were documented. Treatment outcomes were grouped as complete and partial healing, no response and deterioration. RESULTS: Twenty-five patients underwent a median of 12 HBOT sessions for HC occurring after CT and HSCT. Complete healing was observed in 11 patients whereas haematuria improved in seven patients. HC grades after HBOT were significantly better than referral grades. A significant correlation was shown with the number of HBOT sessions and change in haematuria. Patients who underwent seven or more HBOT sessions benefitted most. CONCLUSIONS: HBOT appears to be a safe and effective treatment for refractory HC following CT and HSCT. Higher quality evidence would be needed to prove efficacy. However, given the difficulty of conducting randomised controlled trials on such a vulnerable and small group of patients with few treatment options, and given the consistency of current observational evidence, HC occurring after CT and HSCT may be considered as an optional or investigational indication for HBOT. Copyright: This article is the copyright of the authors who grant Diving and Hyperbaric Medicine a non-exclusive licence to publish the article in electronic and other forms.
Entities:
Keywords:
Cyclophosphamide; Hematopoietic stem cell transplantation; Hemorrhagic cystitis; Hyperbaric research
Authors: K Hosokawa; H Yamazaki; T Nakamura; T Yoroidaka; T Imi; Y Shima; K Ohata; H Takamatsu; T Kotani; Y Kondo; A Takami; S Nakao Journal: Transpl Infect Dis Date: 2014-07-12 Impact factor: 2.228
Authors: K Hattori; M Yabe; M Matsumoto; Y Kudo; Y Yasuda; H Inoue; S Minami; H Miyakita; N Kawamura; K Komori; I Yamamoto; H Yabe Journal: Bone Marrow Transplant Date: 2001-06 Impact factor: 5.483
Authors: Jeffrey S Cooper; Peter Allinson; Dana Winn; Lon Keim; Joe Sippel; Patty Shalberg; Kari Fowler Journal: Undersea Hyperb Med Date: 2015 Sep-Oct Impact factor: 0.698
Authors: Stephan Degener; Alexander Pohle; Hartmut Strelow; Michael J Mathers; Jürgen Zumbé; Stephan Roth; Alexander S Brandt Journal: BMC Urol Date: 2015-05-08 Impact factor: 2.264